Findings on siRNA-Based Therapy Detailed by Investigators at University of Technology Sydney (Targeted Polymer Lipid Hybrid Nanoparticles for In-vitro Sirna Therapy In Triple-negative Breast Cancer).

The article focuses on a novel approach using targeted polymer-lipid hybrid nanoparticles for siRNA-based therapy in triple-negative breast cancer (TNBC). Topics include the development and characterization of PLGA lipid nanoparticles conjugated with an EGFR antibody, the effectiveness of these nanoparticles in silencing the XBP1 gene, and the enhanced targeting and therapeutic impact observed under hypoxic conditions.